Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9778MR)

This product GTTS-WQ9778MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9778MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1442MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ15988MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ3475MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ14386MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ2495MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ6777MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ10641MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ904MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW